Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report

Following the ATTRACTION-2 study, nivolumab was approved for advanced gastric cancer in Japan. However, pseudoprogression and hyperprogressive disease have been reported in patients treated with immune checkpoint inhibitors. We report a patient with gastric cancer who received nivolumab after radiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Takatsugu, Satake, Hironaga, Ogata, Misato, Hatachi, Yukimasa, Yasui, Hisateru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903152/
https://www.ncbi.nlm.nih.gov/pubmed/29681813
http://dx.doi.org/10.1159/000487477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903152/
https://www.ncbi.nlm.nih.gov/pubmed/29681813
http://dx.doi.org/10.1159/000487477

Ejemplares similares